published meta-analysis   sensitivity analysis   studies

ivermectin in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsOkumuş, 2020 0.58 [0.18; 1.91] 0.58[0.18; 1.91]Okumuş, 202010%60NAnot evaluable clinical improvementdetailed resultsOkumuş, 2020 1.51 [0.54; 4.24] 1.51[0.54; 4.24]Okumuş, 202010%60NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-03-29 03:36 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 684,886 - roots T: 290